Non-surgical periocular nodular-BCC treatments are successful

Article

Imiquimod (IMQ) 5% cream and radiotherapy (RT) are both effective for treating periocular nodular-based cell carcinoma (BCC)

Imiquimod (IMQ) 5% cream and radiotherapy (RT) are both effective for treating periocular nodular-based cell carcinoma (BCC), according to a study published in the British Journal of Ophthalmology.

Dr Elena Garcia-Martin et al., Hospital Universitario Miguel Servet, Zaragoza, Spain, examined 27 patients with clinical and histopathological diagnosis of nodular BCC on the eyelid. IMQ 5% cream was administered in 15 patients once daily 5 days a week for 6 weeks. RT was performed in 12 patients.

Within 3 months of treatment all patients demonstrated histopathological remission. Sustained clinical remission was recorded in every patient after 24 months follow-up. Toleration of treatment for IMQ and RT was recorded as moderate and good, respectively.

The investigation concluded that the non-surgical methods of using IMQ and RT were successful in treating eyelid nodular BCCs. IMQ demonstrated better cosmesis and functional results, whereas RT demonstrated a better tolerability.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.